COVID-19: Tips for Eating Healthy While Social Distancing
This article was contributed by Oncology Dietitian and Clinical Exercise Physiologist, Hannah Manella, MS, RD,…
Lymphoma News
Understanding COVID-19/Novel Coronavirus: What Lymphoma Patients Need to Know
Download the Understanding COVID-19/Novel Coronavirus: What Patients Need to Know Fact Sheet. What is COVID-19/coronavirus…
Patient Perspectives: Study Explores Unmet Needs of Lymphoma Patients and Caregivers
Due to an increase in new and effective treatments, outcomes among lymphoma patients have improved,…
Understanding Cancer-Related Financial Toxicity
Understanding Cancer-Related Financial Toxicity Cancer is one of the costliest conditions to treat today in…
U.S. Food and Drug Administration Approves Acalabrutinib (CALQUENCE) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This approval expands the use of acalabrutinib, which received accelerated approval from the FDA for the treatment of adult patients with mantle cell lymphoma (MCL).
U.S. Food and Drug Administration Approves Zanubrutinib (BRUKINSA) for Mantle Cell Lymphoma (MCL)
The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy.
U.S. Food and Drug Administration Approves Pegfilgrastim-bmez (Ziextenzo) for Long-Acting Oncology Supportive Care
Pegfilgrastim-bmez (Ziextenzo, Sandoz) is indicated to decrease the incidence of infection, as manifested by febrile neutropenia for patients with nonmyeloid malignancies who are receiving myelosuppressive anti-cancer therapy.
Lymphoma Research Foundation Update on Vincristine Supply
The Lymphoma Research Foundation is aware that the supply of the vital chemotherapy medicine vincristine…
U.S. Food and Drug Administration Requests Voluntary Recall of Textured Implants Linked to Breast Implant-Associated Anaplastic Large Cell Lymphoma
The U.S. Food and Drug Administration (FDA) requested the voluntary recall from Allergan in reference…
U.S. Food and Drug Administration Approves Biosimilar Rituximab-pvvr (Ruxience) for CD20-positive non-Hodgkin B-cell Lymphomas and Chronic Lymphocytic Leukemia
On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved…
Stay informed with news, alerts and other resources.
